Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03219970
Recruitment Status : Completed
First Posted : July 18, 2017
Last Update Posted : November 25, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 28, 2020
Actual Study Completion Date : October 28, 2020